Clinical trial with 2% sodium cromoglycate (Opticrom) in vernal keratoconjunctivitis.
An open assessment study was carried out during the summer of 1972 in which 2% sodium cromoglycate eyedrops were evaluated in the treatment of patients with vernal keratoconjunctivitis. A highly significant number of patients found the eyedrops effective, while a marked improvement was recorded in mild and moderate cases; in severe cases or in acute exacerbations additional steroid therapy was recommended. Sodium cromoglycate eyedrops were found to be as effective as Decadron and superior to Antistin-Privine. Furthermore SCG eyedrops could replace or reduce local steroid therapy in vernal keratoconjuntivitis and so avert the possible rise in ocular tension caused by steroids.
D000293:Adolescent; D000328:Adult; D000865:Antazoline / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007637:Keratoconjunctivitis / Q000188:drug therapy*; D008297:Male; D009278:Naphazoline / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D012621:Seasons
D004338:Drug Combinations; D009883:Ophthalmic Solutions; D003907:Dexamethasone; D000865:Antazoline; D009278:Naphazoline; D004205:Cromolyn Sodium